HCM
ITCI icon

Hodges Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Hodges Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-40,000
Closed -$2.15M – 297
2015
Q4 		$2.15M Hold
40,000
– – 0.09% 126
2015
Q3 		$1.6M Buy
+40,000
New +$1.3M 0.07% 147

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock Advisors
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Hodges Capital Management's ITCI Position: Q1 2016 in Review

Hodges Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2016, closing a stake of 40,000 shares — an estimated $2.15M sold.

Hodges Capital Management first reported a position in ITCI in Q3 2015 and held it in 2 quarters. The position peaked at $2.15M in Q4 2015. 127 funds tracked by Wall St. Rank hold ITCI as of Q1 2016.

  • Hodges Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2016 after selling out during the quarter.
  • Hodges Capital Management sold 40,000 Intra-Cellular Therapies Inc. shares in Q1 2016, an estimated $2.15M.
  • Hodges Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 2 quarters.
  • Hodges Capital Management's Intra-Cellular Therapies Inc. position peaked at $2.15M in Q4 2015.
  • 127 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2016.

Based on Hodges Capital Management's 13F filing for Q1 2016, filed 26 May 2016.